Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ophthalmology guidance looms but industry still has no endpoints to focus on

This article was originally published in Scrip

Executive Summary

The European Medicines Agency is edging closer to producing the first ever guidance for developing ophthalmology drugs after a two day meeting with industry, healthcare professionals and patients on 27-28 October. Nevertheless, while the agency wanted more discussions and research on various topics, the industry highlighted the need for advice. At the meeting this led to a "chicken and egg frustration," according to Mark Kemp, a Datamonitor analyst who attended the event.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts